National Rural Development Partnership

AHF Applauds Novel Gonorrhea Treatment

Retrieved on: 
Friday, November 3, 2023

AIDS Healthcare Foundation (AHF) applauds promising clinical trial results for a new drug zoliflodacin, which was co-developed by Swiss nonprofit Global Antibiotic Research & Development Partnership and U.S.-based company Innoviva Specialty Therapeutics to treat gonorrhea.

Key Points: 
  • AIDS Healthcare Foundation (AHF) applauds promising clinical trial results for a new drug zoliflodacin, which was co-developed by Swiss nonprofit Global Antibiotic Research & Development Partnership and U.S.-based company Innoviva Specialty Therapeutics to treat gonorrhea.
  • View the full release here: https://www.businesswire.com/news/home/20231103082562/en/
    The "Gonorrhea Alert" billboards, part of an ongoing outdoor advertisement campaign launched by AHF in the U.S., urges the public to visit the www.FreeSTDCheck.org website to learn more about the disease and find locations to access free testing and affordable care in the U.S. for the treatment of sexually transmitted infections.
  • It’s good to see a nonprofit taking the lead in developing a treatment in a space that has not seen significant innovation in many years,” said AHF President Michael Weinstein.
  • Among them is a series of billboards under the theme “ Gonorrhea Alert .”

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Retrieved on: 
Wednesday, November 1, 2023

These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens.

Key Points: 
  • These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens.
  • It also paves the way for a new research and development model in the global fight against antimicrobial resistance (AMR).
  • Now, the positive results of this landmark Phase 3 trial confirm that zoliflodacin has the potential to tackle the most difficult-to-treat gonorrhea infections.
  • This builds on the critical Phase 2 clinical trial sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID).

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, November 1, 2023

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.

Key Points: 
  • Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.
  • "The third quarter of 2023 was marked by significant revenues stemming from our royalty portfolio and solid performance by our internal product portfolio,” said Pavel Raifeld, Chief Executive Officer of Innoviva.
  • During the third quarter of 2023, Innoviva repurchased 856,750 shares of its outstanding common stock for $11.0 million.
  • On August 21, 2023, Innoviva appointed Stephen Basso as Chief Financial Officer.

Critical agreement paves way for new model to accelerate access to important antibiotics for serious bacterial infections

Retrieved on: 
Tuesday, September 12, 2023

Launched in June 2022, the project represents a new model for bridging global gaps in equitable access to important antibiotics.

Key Points: 
  • Launched in June 2022, the project represents a new model for bridging global gaps in equitable access to important antibiotics.
  • Even though populations in low- and middle-income countries face a high burden of death from drug-resistant bacterial infections, their access to antibiotics with activity against resistant bacteria is usually delayed by more than a decade .
  • That situation may worsen given that the number of serious, potentially life-threatening, infections due to carbapenem-resistant bacteria has been growing across multiple regions , including South Asia and Latin America.
  • By addressing barriers that have historically limited the availability of important antibiotics in low- and middle-income countries, this innovative project aims to accelerate appropriate access for an affordable, quality-assured antibiotic to treat drug-resistant Gram-negative infections.

Registrational Phase III trial in Type 1 Diabetes with Diamyd® expands to the US

Retrieved on: 
Tuesday, September 5, 2023

STOCKHOLM, Sept. 5, 2023 /PRNewswire/ -- Final preparations are in place to initiate the first clinical site for DIAGNODE-3 in the United States, and additional sites are expected to be initiated over the coming months. Approximately 10-12 clinical sites across the US are planned to be initiated, expanding the DIAGNODE-3 trial in the US and eight European countries to approximately 60 clincal sites in total. An Investigators' Meeting for the US clinical sites will be held on September 15th in Washington DC with several US key opinion leaders in attendance.

Key Points: 
  • The first clinical site in the United States is pending imminent initiation in the precision medicine Phase III trial DIAGNODE-3, which is ongoing in eight European countries.
  • The goal is to have the trial fully enrolled in the second half of 2024.
  • "This shows the operational and clinical feasibility of our precision medicine approach to Type 1 Diabetes and we look forward to expanding the trial to the United States".
  • The partnership with JDRF, the largest Type 1 Diabetes patient advocacy organisation in the US, forms the backbone of Diamyd Medical's focus on completing enrolment of the registrational trial within the expected timeframe.

Registrational Phase III trial in Type 1 Diabetes with Diamyd® expands to the US

Retrieved on: 
Tuesday, September 5, 2023

STOCKHOLM, Sept. 5, 2023 /PRNewswire/ -- Final preparations are in place to initiate the first clinical site for DIAGNODE-3 in the United States, and additional sites are expected to be initiated over the coming months. Approximately 10-12 clinical sites across the US are planned to be initiated, expanding the DIAGNODE-3 trial in the US and eight European countries to approximately 60 clincal sites in total. An Investigators' Meeting for the US clinical sites will be held on September 15th in Washington DC with several US key opinion leaders in attendance.

Key Points: 
  • The first clinical site in the United States is pending imminent initiation in the precision medicine Phase III trial DIAGNODE-3, which is ongoing in eight European countries.
  • The goal is to have the trial fully enrolled in the second half of 2024.
  • "This shows the operational and clinical feasibility of our precision medicine approach to Type 1 Diabetes and we look forward to expanding the trial to the United States".
  • The partnership with JDRF, the largest Type 1 Diabetes patient advocacy organisation in the US, forms the backbone of Diamyd Medical's focus on completing enrolment of the registrational trial within the expected timeframe.

GigNet Names A. William Allen III to its Board of Directors

Retrieved on: 
Friday, June 16, 2023

GigNet, a Digital Transformation company that provides high-speed broadband and advanced value-added services to enterprise clients and residential communities based on its extensive fiber-optic network from Cancun to Tulum, announced today that A. William Allen III (Bill Allen) has been named to the GigNet Board of Directors.

Key Points: 
  • GigNet, a Digital Transformation company that provides high-speed broadband and advanced value-added services to enterprise clients and residential communities based on its extensive fiber-optic network from Cancun to Tulum, announced today that A. William Allen III (Bill Allen) has been named to the GigNet Board of Directors.
  • His passion is to assist dynamic growth companies to scale successfully by formulating effective strategies and efficiently accessing capital markets.
  • Bloomin’ Brands is a portfolio of casual dining brands, including Outback Steakhouse, Carrabba’s Italian Grill, Fleming’s Prime Steakhouse & Wine Bar, and Bonefish Grill.
  • As CEO of Bloomin’ Brands for five years he was responsible for taking Bloomin Brands private in a US$4.1 billion transaction approved by shareholders.

Zucara Therapeutics Announces Additional Funding from JDRF to Support ZT-01 Phase 2 Study

Retrieved on: 
Thursday, June 15, 2023

Through its Industry Discovery & Development Partnerships ("IDDP") program, JDRF will provide US$2 million in funding to support Zucara's planned Phase 2a study of the effect of ZT-01 On Nocturnal hypoglycemia Events in Type 1 diabetes mellitus ("ZONE").

Key Points: 
  • Through its Industry Discovery & Development Partnerships ("IDDP") program, JDRF will provide US$2 million in funding to support Zucara's planned Phase 2a study of the effect of ZT-01 On Nocturnal hypoglycemia Events in Type 1 diabetes mellitus ("ZONE").
  • Zucara expects to begin patient dosing in the third quarter of 2023.
  • "JDRF has been a long-time partner of Zucara, supporting the development of ZT-01 from early discovery studies to this planned Phase 2 study soon underway," said Richard Liggins PhD, Zucara Therapeutics' Chief Scientific Officer.
  • "JDRF is excited to support Zucara's development of a novel therapy with the potential to protect against nocturnal hypoglycemia and help people with T1D achieve better glucose control."

Diamyd Medical partners with JDRF to advance the DIAGNODE-3 Phase 3 trial in Type 1 Diabetes

Retrieved on: 
Tuesday, April 4, 2023

STOCKHOLM, April 4, 2023 /PRNewswire/ -- Diamyd Medical and JDRF, the leading global type 1 diabetes research and advocacy organization, have entered into a four-year research and development collaboration including a non-dilutive $5 million award to Diamyd Medical to support its ongoing Phase 3 trial with the precision medicine antigen-specific immunotherapy Diamyd®.

Key Points: 
  • STOCKHOLM, April 4, 2023 /PRNewswire/ -- Diamyd Medical and JDRF, the leading global type 1 diabetes research and advocacy organization, have entered into a four-year research and development collaboration including a non-dilutive $5 million award to Diamyd Medical to support its ongoing Phase 3 trial with the precision medicine antigen-specific immunotherapy Diamyd®.
  • "JDRF is committed to supporting and advancing disease modifying therapies to delay and reverse type 1 diabetes," said Sanjoy Dutta, Ph.D., chief scientific officer at JDRF.
  • "We are excited about Diamyd Medical's groundbreaking Phase 3 trial and its potential advancements in the preservation of insulin production for people recently diagnosed with type 1 diabetes."
  • "JDRF's commitment to this Phase 3 program is a validation of the scientific and clinical value of the antigen-specific immunotherapy Diamyd.

Diamyd Medical partners with JDRF to advance the DIAGNODE-3 Phase 3 trial in Type 1 Diabetes

Retrieved on: 
Tuesday, April 4, 2023

STOCKHOLM, April 4, 2023 /PRNewswire/ -- Diamyd Medical and JDRF, the leading global type 1 diabetes research and advocacy organization, have entered into a four-year research and development collaboration including a non-dilutive $5 million award to Diamyd Medical to support its ongoing Phase 3 trial with the precision medicine antigen-specific immunotherapy Diamyd®.

Key Points: 
  • STOCKHOLM, April 4, 2023 /PRNewswire/ -- Diamyd Medical and JDRF, the leading global type 1 diabetes research and advocacy organization, have entered into a four-year research and development collaboration including a non-dilutive $5 million award to Diamyd Medical to support its ongoing Phase 3 trial with the precision medicine antigen-specific immunotherapy Diamyd®.
  • "JDRF is committed to supporting and advancing disease modifying therapies to delay and reverse type 1 diabetes," said Sanjoy Dutta, Ph.D., chief scientific officer at JDRF.
  • "We are excited about Diamyd Medical's groundbreaking Phase 3 trial and its potential advancements in the preservation of insulin production for people recently diagnosed with type 1 diabetes."
  • "JDRF's commitment to this Phase 3 program is a validation of the scientific and clinical value of the antigen-specific immunotherapy Diamyd.